核苷类似物治疗乙型肝炎病毒感染相关肝衰竭患者的临床研究进展

Advances in treatment of HBV-related liver failure with nucleoside analogues

乙型肝炎病毒感染是我国肝功能衰竭的常见原因,乙型重型肝炎病死率高达70%以上.与其他原因所致肝功能衰竭不同,在治疗上除综合治疗外,是否进行抗病毒治疗是近年研究的热点.由于乙型肝炎病毒的复制在乙型重型肝炎的发生发展中起着始动或主导作用,因此,通过抗病毒治疗降低病毒载量,缓解过强的免疫反应,从而缓解病情,是乙型重型肝炎治疗的新思路.核苷类抗病毒药物的问世,使乙型重型肝炎抗病毒治疗成为可能.本文就该领域的研究现状作一综述.

Hepatitis B virus（HBV） infection is a common cause of liver failure in China.The mortality of fulminant hepatitis B is more than 70%.Adoption of antiviral therapy or not on the basis of comprehensive treatment has become a hot topic of recent research of treatment of fulminant hepatitis B,which causes liver failure in a way different from other reasons.HBV replication plays a critical role in initiating the development of fulminant hepatitis B.Reducing viral load to alleviate excessive immune response by antiviral therapy represents a new idea for the treatment of fulminant hepatitis B.The advent of nucleoside analogues makes it possible to conduct antiviral therapy against fulminant hepatitis B.This article summarizes recent advances in treatment of HBV-related liver failure with nucleoside analogues.